“The vast majority of epitopes in the N proteins of different strains of SARS-CoV-2 remain identical, so we can expect an almost identical immune response when a person vaccinated with Convasel encounters all strains of the SARS-CoV-2 virus, including those that are now actively developing,” - TASS quotes Skvortsova.
In addition, it was reported that the Russian vaccine "Konvasel" is suitable for revaccination after vaccinations with the drugs "Sputnik V", "EpiVacCorona" and "KoviVac".
Earlier, the FMBA announced the launch of industrial production of the Convasel vaccine.
Post-registration trials are planned for the end of summer 2022.
Skvortsova, on the air of the Russia 24 channel, said that among those who were vaccinated with the Konvasel coronavirus vaccine as part of clinical trials, no one fell ill with COVID-19.